At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 6 enrolled
Drug / intervention
BKR-017drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Colonic Delivery of Butyrate to Improve Insulin Sensitivity and Lower Triglycerides in Type 1 Diabetes Subjects
In Brief
A Phase 2 clinical trial evaluating BKR-017 for Type1diabetes. Completed, enrolled 6 participants across 1 site.
Detailed Summary
The investigators are interested to evaluate the effect of BKR-017 (colon-targeted 500 mg butyrate tablets) as adjuvant therapy on metabolic control in type 1 diabetes (TID) subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType1diabetes
CountriesUnited States
CollaboratorsBioKier Inc., Juvenile Diabetes Research Foundation
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJun 2019
Enrollment StartJul 2022
Primary CompletionApr 2025
Study CompletionDec 2025
TodayJul 2026
First PostedJun 27, 2019
Enrollment StartJul 28, 2022
Primary CompletionApr 1, 2025
Study CompletionDec 1, 2025
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 7.0 years ago
Interventions
BKR-017drug
BKR-017